The DOI matches its Crossref record; 139 of the 139 references it cites were found in a registry or an index.
Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: Selected practical issues in their evaluation and management†
Open accessAbstract
UNLABELLED: Nonalcoholic fatty liver disease (NAFLD) is among the most common causes of chronic liver disease in the western world. It is now recognized that these patients have myriad of important co-morbidities (e.g., diabetes, hypothyroidism and metabolic syndrome). The workup of patients with suspected NAFLD should consist of excluding competing etiologies and systemic evaluation of metabolic comorbidities. NAFLD is histologically categorized into steatosis and steatohepatitis, two states with fairly dichotomous natural history. While significant progress has been made in terms of noninvasively predicting advanced fibrosis, insufficient progress has been made in predicting steatohepatitis. Currently, liver biopsy remains the gold standard for the histological stratification of NAFLD. While sustained weight loss can be effective to treat NASH, it is often difficult to achieve. Foregut bariatric surgery can be quite effective in improving hepatic histology in selected patients without liver failure or significant portal hypertension. Thiazolidinediones have shown promise and the results from the ongoing, large multicenter study should become available soon. Large multicenter studies of CB, receptor anatagonists are also underway but their results will not be available for several years. Several recent studies have highlighted that cardiovascular disease is the single most important cause of morbidity and mortality in this patient population. CONCLUSION: Health care providers should not only focus on liver disease but also concentrate on aggressively modifying and treating their cardiovascular risk factors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Angelico, F., Burattin, M., Alessandri, C., Ben, M. D., & Lirussi, F. (2007) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005166.pub2 · Cited by 133
RetractedReduction in the incidence of type 2 diabetes with lifestyle intervention or metformin
(2002) · New England Journal of Medicine · doi:10.1056/nejmoa012512 · Cited by 19,011
Design and validation of a histological scoring system for nonalcoholic fatty liver disease†
Kleiner, D. E., Brunt, E. M., Van Natta, M., Behling, C., Contos, M. J., Cummings, O. W., Ferrell, L. D., Liu, Y., Torbenson, M. S., Unalp‐Arida, A., et al. (2005) · Hepatology · doi:10.1002/hep.20701 · Cited by 10,791
Nonalcoholic Fatty Liver Disease
Angulo, P. (2002) · New England Journal of Medicine · doi:10.1056/nejmra011775 · Cited by 5,228
Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes
Nissen, S. E., & Wolski, K. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa072761 · Cited by 4,675
Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery
Sjöström, L., Lindroos, A.-K., Peltonen, M., Torgerson, J., Bouchard, C., Carlsson, B., Dahlgren, S., Larsson, B., Narbro, K., Sjöström, C. D., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa035622 · Cited by 4,457
Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity.
MATTEONI, C., YOUNOSSI, Z., GRAMLICH, T., BOPARAI, N., LIU, Y., & MCCULLOUGH, A. (1999) · Gastroenterology · doi:10.1016/s0016-5085(99)70506-8 · Cited by 3,345
Angulo, P., Hui, J. M., Marchesini, G., Bugianesi, E., George, J., Farrell, G. C., Enders, F., Saksena, S., Burt, A. D., Bida, J. P., et al. (2007) · Hepatology · doi:10.1002/hep.21496 · Cited by 3,203
The Natural History of Nonalcoholic Fatty Liver Disease: A Population-Based Cohort Study
Adams, L. A., Lymp, J. F., St. Sauver, J., Sanderson, S. O., Lindor, K. D., Feldstein, A., & Angulo, P. (2005) · Gastroenterology · doi:10.1053/j.gastro.2005.04.014 · Cited by 2,890
Nonalcoholic Fatty Liver, Steatohepatitis, and the Metabolic Syndrome
Marchesini, G., Bugianesi, E., Forlani, G., Cerrelli, F., Lenzi, M., Manini, R., Natale, S., Vanni, E., Villanova, N., Melchionda, N., et al. (2003) · Hepatology · doi:10.1053/jhep.2003.50161 · Cited by 2,679
Cited by
Chalasani, N., Younossi, Z., Lavine, J. E., Charlton, M., Cusi, K., Rinella, M., Harrison, S. A., Brunt, E. M., & Sanyal, A. J. (2018) · Hepatology · doi:10.1002/hep.29367 · Cited by 7,239
Self-citationChalasani, N., Younossi, Z., Lavine, J. E., Diehl, A. M., Brunt, E. M., Cusi, K., Charlton, M., & Sanyal, A. J. (2012) · Hepatology · doi:10.1002/hep.25762 · Cited by 3,803
Self-citationChalasani, N., Younossi, Z., Lavine, J. E., Diehl, A. M., Brunt, E. M., Cusi, K., Charlton, M., & Sanyal, A. J. (2012) · Gastroenterology · doi:10.1053/j.gastro.2012.04.001 · Cited by 1,775
Self-citationMartin, P., DiMartini, A., Feng, S., Brown, R., & Fallon, M. (2014) · Hepatology · doi:10.1002/hep.26972 · Cited by 1,045
Xiao, G., Zhu, S., Xiao, X., Yan, L., Yang, J., & Wu, G. (2017) · Hepatology · doi:10.1002/hep.29302 · Cited by 895
Pathogenesis of non-alcoholic fatty liver disease
Dowman, J. K., Tomlinson, J. W., & Newsome, P. N. (2010) · QJM · doi:10.1093/qjmed/hcp158 · Cited by 741
Validity of real time ultrasound in the diagnosis of hepatic steatosis: A prospective study
Dasarathy, S., Dasarathy, J., Khiyami, A., Joseph, R., Lopez, R., & McCullough, A. J. (2009) · Journal of Hepatology · doi:10.1016/j.jhep.2009.09.001 · Cited by 656
Csak, T., Ganz, M., Pespisa, J., Kodys, K., Dolganiuc, A., & Szabo, G. (2011) · Hepatology · doi:10.1002/hep.24341 · Cited by 645
Chalasani, N., Younossi, Z., Lavine, J. E., Diehl, A. M., Brunt, E. M., Cusi, K., Charlton, M., & Sanyal, A. J. (2012) · American Journal of Gastroenterology · doi:10.1038/ajg.2012.128 · Cited by 585
Self-citationLaBrecque, D. R., Abbas, Z., Anania, F., Ferenci, P., Khan, A. G., Goh, K.-L., Hamid, S. S., Isakov, V., Lizarzabal, M., Peñaranda, M. M., et al. (2014) · Journal of Clinical Gastroenterology · doi:10.1097/mcg.0000000000000116 · Cited by 519
Histopathology of nonalcoholic fatty liver disease
Brunt, E. M. (2010) · World Journal of Gastroenterology · doi:10.3748/wjg.v16.i42.5286 · Cited by 449
Hepatic Steatosis: Quantification by Proton Density Fat Fraction with MR Imaging versus Liver Biopsy
Idilman, I. S., Aniktar, H., Idilman, R., Kabacam, G., Savas, B., Elhan, A., Celik, A., Bahar, K., & Karcaaltincaba, M. (2013) · Radiology · doi:10.1148/radiol.13121360 · Cited by 389
Validation of the FIB4 index in a Japanese nonalcoholic fatty liver disease population
Sumida, Y., Yoneda, M., Hyogo, H., Itoh, Y., Ono, M., Fujii, H., Eguchi, Y., Suzuki, Y., Aoki, N., Kanemasa, K., et al. (2012) · BMC Gastroenterology · doi:10.1186/1471-230x-12-2 · Cited by 383
Liver natural killer and natural killer T cells: immunobiology and emerging roles in liver diseases
Gao, B., Radaeva, S., & Park, O. (2009) · Journal of Leukocyte Biology · doi:10.1189/jlb.0309135 · Cited by 377
de Lédinghen, V., Vergniol, J., Foucher, J., Merrouche, W., & le Bail, B. (2012) · Liver International · doi:10.1111/j.1478-3231.2012.02820.x · Cited by 367
Nonalcoholic Fatty Liver Disease: A Review and Update
Lewis, J. R., & Mohanty, S. R. (2010) · Digestive Diseases and Sciences · doi:10.1007/s10620-009-1081-0 · Cited by 345
Dowman, J. K., Tomlinson, J. W., & Newsome, P. N. (2011) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2010.04556.x · Cited by 312
Current treatment paradigms and emerging therapies for NAFLD/NASH
Raza, S. (2021) · Frontiers in Bioscience · doi:10.2741/4892 · Cited by 310
Setiawan, V. W., Stram, D. O., Porcel, J., Lu, S. C., Le Marchand, L., & Noureddin, M. (2016) · Hepatology · doi:10.1002/hep.28677 · Cited by 302
Practice guidelines for the diagnosis and management of nonalcoholic fatty liver disease
Loria, P., Adinolfi, L. E., Bellentani, S., Bugianesi, E., Grieco, A., Fargion, S., Gasbarrini, A., Loguercio, C., Lonardo, A., Marchesini, G., et al. (2010) · Digestive and Liver Disease · doi:10.1016/j.dld.2010.01.021 · Cited by 294
Soft drink consumption is associated with fatty liver disease independent of metabolic syndrome
Abid, A., Taha, O., Nseir, W., Farah, R., Grosovski, M., & Assy, N. (2009) · Journal of Hepatology · doi:10.1016/j.jhep.2009.05.033 · Cited by 287
Nonalcoholic fatty liver disease: an emerging threat to obese and diabetic individuals
Masuoka, H. C., & Chalasani, N. (2013) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.12016 · Cited by 283
Self-citationPoudyal, H., Campbell, F., & Brown, L. (2010) · The Journal of Nutrition · doi:10.3945/jn.109.117812 · Cited by 283
Molecular mechanisms involved in NAFLD progression
Malaguarnera, M., Di Rosa, M., Nicoletti, F., & Malaguarnera, L. (2009) · Journal of Molecular Medicine · doi:10.1007/s00109-009-0464-1 · Cited by 282
Kawamura, Y., Arase, Y., Ikeda, K., Seko, Y., Imai, N., Hosaka, T., Kobayashi, M., Saitoh, S., Sezaki, H., Akuta, N., et al. (2012) · American Journal of Gastroenterology · doi:10.1038/ajg.2011.327 · Cited by 280
Therapeutic pipeline in nonalcoholic steatohepatitis
Vuppalanchi, R., Noureddin, M., Alkhouri, N., & Sanyal, A. J. (2021) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-020-00408-y · Cited by 278
Self-citationFAN, J. G., JIA, J. D., LI, Y. M., WANG, B. Y., LU, L. G., SHI, J. P., CHAN, L. Y., & CHINESE ASSOCIATION FOR THE STUDY OF LIVER DISEASE (2011) · Journal of Digestive Diseases · doi:10.1111/j.1751-2980.2010.00476.x · Cited by 278
The role of adiponectin in the pathogenesis and treatment of non‐alcoholic fatty liver disease
Polyzos, S. A., Kountouras, J., Zavos, C., & Tsiaousi, E. (2010) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2009.01176.x · Cited by 277
Signal Transducer and Activator of Transcription 3 in Liver Diseases: A Novel Therapeutic Target
Wang, H., Lafdil, F., Kong, X., & Gao, B. (2011) · International Journal of Biological Sciences · doi:10.7150/ijbs.7.536 · Cited by 269
Loguercio, C., Andreone, P., Brisc, C., Brisc, M. C., Bugianesi, E., Chiaramonte, M., Cursaro, C., Danila, M., de Sio, I., Floreani, A., et al. (2012) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2012.02.008 · Cited by 267
Gastrointestinal complications of diabetes mellitus
Krishnan, B. (2013) · World Journal of Diabetes · doi:10.4239/wjd.v4.i3.51 · Cited by 226
Inzaugarat, M. E., Ferreyra Solari, N. E., Billordo, L. A., Abecasis, R., Gadano, A. C., & Cherñavsky, A. C. (2011) · Journal of Clinical Immunology · doi:10.1007/s10875-011-9571-1 · Cited by 115
Bril, F., Portillo Sanchez, P., Lomonaco, R., Orsak, B., Hecht, J., Tio, F., & Cusi, K. (2017) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2017-00867 · Cited by 97
IL-33 treatment attenuated diet-induced hepatic steatosis but aggravated hepatic fibrosis
Gao, Y., Liu, Y., Yang, M., Guo, X., Zhang, M., Li, H., Li, J., & Zhao, J. (2016) · Oncotarget · doi:10.18632/oncotarget.9259 · Cited by 79
Tanaka, N., Zhang, X., Sugiyama, E., Kono, H., Horiuchi, A., Nakajima, T., Kanbe, H., Tanaka, E., Gonzalez, F. J., & Aoyama, T. (2010) · Biochemical Pharmacology · doi:10.1016/j.bcp.2010.07.031 · Cited by 78
Zhang, R.-N., Pan, Q., Zhang, Z., Cao, H.-X., Shen, F., & Fan, J.-G. (2015) · Hepatitis Monthly · doi:10.5812/hepatmon.15(5)2015.27909 · Cited by 56
Chung, K. W., Lee, E. K., Kim, D. H., An, H. J., Kim, N. D., Im, D. S., Lee, J., Yu, B. P., & Chung, H. Y. (2015) · Aging Cell · doi:10.1111/acel.12305 · Cited by 41
Non-alcoholic fatty liver disease resolution following sleeve gastrectomy
Algooneh, A., Almazeedi, S., Al-Sabah, S., Ahmed, M., & Othman, F. (2016) · Surgical Endoscopy · doi:10.1007/s00464-015-4426-0 · Cited by 36
Maleki, I. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i35.12566 · Cited by 22
Metadata
- Authors
- Vuppalanchi, R., & Chalasani, N.
- Venue
- Hepatology
- Published
- 2009-01
- Volume
- 49
- Issue
- 1
- Pages
- 306-317
- ISSN
- 0270-9139 (ISSN-L)
- OpenAlex
- W1984669204
- Cited by
- 563
- References
- 139
- FWCI
- 32.63
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.